Nasdaq Issues Second Delisting Notice to Aimei Health for Delayed Quarterly Report
AFJK has more than doubled off its 52-week low of $6.75.
Summary
Aimei Health received another Nasdaq delisting notice for its overdue quarterly report, compounding prior compliance issues and raising delisting concerns.
Key Events · Corporate Governance and Compliance · AFJK
-
Second Nasdaq Deficiency Notice
The company received a notice on May 19, 2026, for failing to file its Quarterly Report on Form 10-Q by the May 15, 2026 deadline.
-
Escalating Compliance Issues
This follows a previous Nasdaq deficiency notice for the company's delayed Annual Report on Form 10-K (filed April 21, 2026), highlighting a pattern of non-compliance with listing rules.
-
Increased Delisting Risk
While there is no immediate effect on trading, continued non-compliance with Nasdaq's listing rules could lead to the delisting of the company's securities.
-
Going Concern Context
This new deficiency adds to the company's precarious financial situation, which includes a "going concern" warning disclosed in its recent 10-K filing (May 4, 2026).
Analysis · AFJK · Real Estate & Construction
Aimei Health Technology has received a second Nasdaq deficiency notice, this time for failing to timely file its Form 10-Q. This follows a similar notice for its annual 10-K report and a "going concern" warning, indicating persistent financial reporting and compliance issues. The accumulation of these notices significantly increases the risk of the company's shares being delisted from Nasdaq.
At the time of this filing, AFJK was trading at $42.18 on NASDAQ in the Real Estate & Construction sector, with a market capitalization of approximately $133.5M. The 52-week trading range was $6.75 to $130.37. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.